Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases
Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …
treatment of Alzheimer's disease (AD) and show significant positive effects in …
New pathways identify novel drug targets for the prevention and treatment of Alzheimer's disease
B Penke, M Szűcs, F Bogár - International Journal of Molecular Sciences, 2023 - mdpi.com
Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disorder. AD is a
complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging …
complex and multifactorial disease that is responsible for 60–80% of dementia cases. Aging …
Cholinergic white matter pathways along the Alzheimer's disease continuum
Previous studies have shown that the cholinergic nucleus basalis of Meynert and its white
matter projections are affected in Alzheimer's disease dementia and mild cognitive …
matter projections are affected in Alzheimer's disease dementia and mild cognitive …
Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease
Patients who have dementia with Lewy bodies and Alzheimer's disease show early
degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter …
degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter …
Structural (dys) connectivity associates with cholinergic cell density in Alzheimer's disease
CP Lin, I Frigerio, BDC Boon, Z Zhou, AJM Rozemuller… - Brain, 2022 - academic.oup.com
Cognitive deficits in Alzheimer's disease, specifically amnestic (memory dominant) deficits,
are associated with cholinergic degeneration in the basal forebrain. The cholinergic nucleus …
are associated with cholinergic degeneration in the basal forebrain. The cholinergic nucleus …
[HTML][HTML] No laughing white matter: Reduced integrity of the cortical cholinergic pathways in Parkinson's disease-related cognitive impairment
RA Crockett, KB Wilkins, S Aditham… - Neurobiology of …, 2023 - Elsevier
Background Approximately one third of recently diagnosed Parkinson's disease (PD)
patients experience cognitive decline. The nucleus basalis of Meynert (NBM) degenerates …
patients experience cognitive decline. The nucleus basalis of Meynert (NBM) degenerates …
Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence
Cognitive impairment is a well‐recognized and debilitating symptom of Parkinson's disease
(PD). Degradation in the cortical cholinergic system is thought to be a key contributor. Both …
(PD). Degradation in the cortical cholinergic system is thought to be a key contributor. Both …
Cholinergic basal forebrain volumes predict gait decline in Parkinson's disease
Background Gait disturbance is an early, disabling feature of Parkinson's disease (PD) that
is typically refractory to dopaminergic medication. The cortical cholinergic system …
is typically refractory to dopaminergic medication. The cortical cholinergic system …
Cortical connectivity of the nucleus basalis of Meynert in Parkinson's disease and Lewy body dementias
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are related
conditions that are associated with cholinergic system dysfunction. Dysfunction of the …
conditions that are associated with cholinergic system dysfunction. Dysfunction of the …
Comparing different approaches for operationalizing subjective cognitive decline: impact on syndromic and biomarker profiles
Subjective cognitive decline (SCD) has been proposed as a risk factor for future cognitive
decline and dementia. Given the heterogeneity of SCD and the lack of consensus about how …
decline and dementia. Given the heterogeneity of SCD and the lack of consensus about how …